Table 3.
Association of fecal calprotectin with pouch inflammation.
| Author | Year | Study design | Patient # | Median age (range) | Pre-op diagnosis | Pouchitis definition | Biomarker | CutOff (µg/g) | Method; assay | Association between biomarker and PDAI | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thomas | 2000 | Prospective cohort | 24 | NP | UC (16) FAP (8) |
Macroscopic inflammation and histologic inflammation | Fcalpro | NP | ELISA; NP |
All patients with inflammation had elevated fcalpro | NP | NP |
| Pronio | 2016 | Prospective cohort | 40 | 52 (33–71) | UC | PDAI ≥ 7 | Fcalpro | 66.2 37.6 |
ELISA; Calprest Test (Eurospital, Trieste, Italy) |
Endoscopy subscore: NP Total PDAI: r = 0.55 p = 0.002 AUC: 0.832 |
85 92 |
38 19 |
| Johnson | 2009 | Prospective cohort | 54 | 47 | UC (46) FAP (8) |
PDAI ≥ 7 | Fcalpro | 92.5 | ELISA; PhilCal Test (Calpro, Oslo, Norway) |
Endoscopy subscore:
r
= 0.605 p≤ 0.0001 Total PDAI:r = 0.71 p ≤ 0.001 |
90 | 76.5 |
| Farkas | 2015 | Prospective cohort | 33 | 30–40 | UC |
PDAI ≥ 7 | Fcalpro | 262 | ELISA; (Quantum Blue, Buhlmann Laboratories Ltd, Schonenbuch) |
Endoscopy Subscore: Significant association w p = 0.0001 Total PDAI: AUC = 0.78 |
67 | 89 |
| Pakarinen | 2010 | Prospective cohort | 32 | 24 (17–31) | UC | Histologic neutrophil count + episodes of pouchitis | Fcalpro | 300 | ELISA; PhilCal Test (Calpro, Oslo, Norway) |
Histologic neutrophil count r = 0.715 p < 0.001 Episodes of pouchitis r = 0.457 p < 0.01 |
57 | 92 |
| Ollech | 2021 | Prospective cohort | 156 | 43 (35–58) | UC | Endoscopic PDAI ≥ 5 | Fcalpro | 462 | ELISA; NP |
Severity of pouchitis r = 0.526 p = 0.0017 |
66.7 | 82.4 |
Abbreviations: AUC: area under the curve; ELISA: enzyme linked immunosorbent assay; FAP: familial adenomatous polyposis; Fcalpro: fecal calprotectin; NP: not provided; PDAI: pouchitis disease activity index; pre-op: pre-operative; UC: ulcerative colitis